Safety and Tolerability of GemRIS 225 mg in Subjects With Muscle-Invasive Bladder Cancer
Status:
Completed
Trial end date:
2019-05-02
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if TAR-200, an investigational drug-delivery
system, is safe and tolerable in patients with muscle-invasive bladder cancer (MIBC) between
diagnosis and radical cystectomy (RC).